Introduction: The use of drugs to enhance recovery ('rehabilitation pharmacology') has been
INTRODUCTION
Stroke units save lives and, coupled with effective treatments such as thrombolysis and improved hyperacute care, more patients are surviving stroke. This, in the presence of an ageing population, has increased the number of stroke survivors, among whom the burden of stroke is high, with many patients left with significant disability. The brain's ability to regenerate and undergo plastic change has long been exploited by rehabilitation; however, now the potential to exploit neuroplasticity with pharmacological agents seems to be a real possibility.
1, 2
Amphetamine, a sympathomimetic drug that leads to the release of noradrenaline and possibly dopamine and serotonin, acts as a stimulant, both centrally and peripherally. 3 In experimental models of stroke, when given in conjunction with task specific practice, amphetamine has been shown to accelerate the recovery of motor function. [4] [5] [6] Improved recovery is only seen when amphetamine is given with training related activity suggesting that in addition to modulation of central neurotransmitters, amphetamine may enhance long term potentiation. Further, amphetamine can result in neural sprouting and enhanced synaptogenesis 7 and augmentation of dendritic length and density, perhaps reflecting enhanced synaptic connectivity. 8 In healthy volunteers, amphetamine can modulate use dependent plasticity, as measured by task specific training performance and simultaneous transcranial magnetic stimulation evoked electromyographic responses. 9 Similarly, in volunteers undergoing functional MRI, increased regional cerebral activation was seen, suggesting that amphetamine may lead to recruitment of neuronal units and/or increased activation within these units.
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Several small trials have assessed the use of amphetamine after stroke and we sought to perform a systematic review to assess its effects on functional outcome and haemodynamic measures.
METHODS

Search strategy
Electronic of all relevant articles and reviews were also checked to identify suitable studies.
The following search strategy was used for MEDLINE and adapted for the other databases: 9. 4 and 8
limit 9 to human
Data collection and analysis
Randomised controlled trials of amphetamine in stroke (ischaemic or haemorrhagic) were selected for inclusion. Trial quality was assessed using standard criteria 11 including determining methods of randomisation, double blinding, participants lost to follow up, generation of random numbers, and allocation concealment. Data were independently extracted from publications, this including outcome measures (by intention-to-treat), ideally at end-of-treatment and at end-of-follow up.
Types of outcome measures
The primary outcome was functional outcome at end-of-follow up as assessed by combined death or disability/dependency, defined as a modified Rankin Scale (mRS) >2 or Barthel Index (BI) <60.
Secondary outcomes included measures of impairment, function and haemodynamic measures, the latter including blood pressure (mmHg) and heart rate (beats per minute).
Data synthesis
Data were analysed by 'intention-to-treat' where available, tested for heterogeneity using I2, and a weighted estimate calculated for the typical treatment effect across trials. Improvement scores were calculated, where possible, to assess change following treatment. Random effects models were used since between-trial sources of heterogeneity were expected, e.g. due to differences in type of treatment regime, outcome scales, and clinical and statistical differences between the trials. Treatment effects were determined using the odds ratio (OR) for dichotomous data and weighted mean difference (WMD) for continuous data, and 95% confidence intervals (CI) calculated. Where different assessment scales were being analysed (such as Fugl-Meyer and Rivermead Motor Assessment Scale) standardised mean difference (SMD) was calculated. The Cochrane Collaboration's Review
Manager software, RevMan 4.2.7, was used for data entry and analysis. Publication bias was assessed visually using a funnel plot and statistically using Eggers plot.
RESULTS
Trials
Eleven completed trials (329 patients) were identified and included in the analysis (figure 1). One ongoing trial was identified, 12 and two trials had recently been terminated early due to problems recruiting patients. 13 14 All but two trials limited inclusion to ischaemic stroke, and recruitment time ranged from within 72 hours to 6 weeks following stroke onset (table 1) . Trial quality overall was good;
one trial was single blind due to safety concerns, but all had blinded assessment of outcomes. Of the eleven trials, 2 are published only in abstract format. 15 
Death or disability/dependency
The combined outcome of death or dependency was only reported in 5 trials (n=206 patients) and treatment with amphetamine did not alter it, OR 1.15 (95% CI 0.65 to 2.06) (figure 2). No change in disability (BI) was seen, WMD 0.12 (95% CI, -4.26-4.61). All 11 trials provided data on mortality and there was a trend for more deaths at the end of follow-up with amphetamine, OR 2.78 (95% CI, 0.75 to
10.23) (figure 3).
Impairment
Motor impairment was the primary outcome in several trials and was recorded in 9 studies (n=257); a trend to better motor scores was present in patients treated with amphetamine, WMD 3.28 (95% CI -0.48 to 7.04). Similarly, analysing change in motor scores from baseline to end-of-trial showed a trend to a better motor score improvement with amphetamine, SMD 0.28 (95% CI, -0.08 to 0.64) (figure 4).
Neurological impairment was assessed in 2 studies (n=67 patients); 17, 18 there were trends to better neurological score (SSS), WMD 2.43 (95% CI, -4.41 to 9.28), and greater change in score between baseline and end-of-treatment, WMD 3.96 (95% CI, -1.23 to 9.15) in the amphetamine group ( figure   9 ).
17, 18
Other outcomes
Two studies analysed language, 19 18 with no difference in language function as assessed by the Porch Communication Score or Sheffield screening score, SMD 0.11 (95% CI, -0.45 to 0.67). Language was the primary outcome in one of these studies 19 and, using a different method of analysis, a statistically significant improvement was seen in language ability. Mood, as assessed with the Zung depression score, did not improve in the amphetamine group, WMD 0.87 points (95% CI, -3.33 to 5.07), in the 2 studies in which it was assessed.
15, 18
Haemodynamics
Haemodynamic data was available in 3 studies (n=106 patients). 17, 18, 20 Systolic and diastolic blood pressure both showed significant increases after dexamphetamine, WMD 9.29 (95% CI, 3.26 to 15.32) (figure 5) and WMD 5.13 (95% CI, 1.61 to 8.64) respectively. Heart rate was also significantly increased with amphetamine, WMD 7.61 (95% CI 1.78 to 13.43) (figure 6).
Heterogeneity and publication bias
Despite variations in treatment regimes, outcomes, and follow-up duration, there was no evidence of significant heterogeneity in any of the analyses. Additionally, there was no evidence of publication bias, either visually or statistically (p= 0.125).
DISCUSSION
Amphetamine was not associated with improvement in the combined outcome of death or dependency after stroke, in keeping with a previous smaller review 21 . Additionally, whilst there were trends to motor and neurological improvement, none of the effects were significant. Furthermore, there remains insufficient data to draw any conclusions regarding the effects of amphetamine on mood or communication or quality of life. This current analysis included data from newly published trials or data not previously available, doubling the available sample size in comparison to earlier review. 21 There are many potential explanations for the lack of treatment effect seen. First, the varying outcome measures limited analysis and may have underestimated or concealed any potential effect. Wide confidence limits highlight the limited available data and make it difficult to draw firm conclusions.
Similarly, many of the outcome measures demonstrate ceiling effects, although some studies excluded patients with mild weakness in an attempt to overcome this. [22] [23] [24] [25] Second, enrolment in a number of studies was completed early due to a low recruitment rate 25 18 so the intended sample size was not achieved thereby leading to a potential type II error. Difficulties recruiting into acute stroke trials with multiple exclusion criteria are well recognised. 26 In two other studies, enrolment was terminated prematurely and the results remain unpublished. 13, 14 Third, amphetamine may not be effective at improving outcome using the dose regimes tested in the available trials. The optimal treatment regime remains uncertain, with data from experimental stroke
showing that a 'bell-shaped' dose response exists, 5 i.e. both low and high doses, as well as early administration, are associated with a poor outcome. 4, 27 In this respect, clinical trials tested lower and less frequent dosing than experimental models, presumably with the aim to reduce potential adverse effects. 4, 5, 28, 29 4, 27, 30 Discrepancy between pre-clinical experiments and clinical trials is well documented in stroke studies and pre-clinical data needs rigorous assessment when utilised in the development of new treatments for stroke. 40 Fourth, it is feasible that baseline imbalances in stroke severity (with more severe stroke in the treatment group) may have concealed a treatment effect. This hypothesis is strengthened by the observation that the treatment effect appears to be greater when assessed in terms of improvement, thus taking into account any baseline imbalance. Unfortunately, limited sample sizes prevent stratification of data by prognostic baseline factors such as stroke syndrome, severity or time to recruitment. Similarly, no clinical study has taken into account the nature of ischaemic lesion, its size and location, which may help target interventions to selected groups of patients. 31 Fifth, significant haemodynamic effects may increase risk factors for a poor outcome with lack of treatment effect reflecting a balance between potential benefit and harm. Both elevations in blood pressure and heart rate are associated with poor outcome after stroke, 32 33 as is impaired baroreceptor sensitivity, with increased cardiac events and arrhythmias. 34 Despite this, the relationship between drug induced haemodynamic changes and outcome remains unclear. Experimental data supporting the use of amphetamine, where no tendency to harm has been demonstrated, have involved healthy volunteers. 9, 35, 36 This is in contrast to clinical studies where stroke patients are older and often have multiple co-morbidities. Similar to results utilising amphetamine in animal stroke models, data derived from the use of amphetamine in healthy volunteers needs cautious interpretation.
Despite concerns regarding increasing heart rate and blood pressure, up to a fifth of acute stroke patients have low blood pressure, and hypotension is also associated with poor outcome. 37 Elevation of systemic blood pressure in the presence of dysfunctional cerebral autoregulation (as occurs in acute ischaemic stroke) might lead to augmentation in cerebral blood flow and, potentially, enhance recovery. 31 Changes in cerebral blood flow with amphetamine have been demonstrated previously, 38 although these appeared to be region-specific and may represent cortical activation rather than systemic augmentation. Monitoring of treatment effects with functional imaging may provide further information on potential mechanisms of amphetamine action, as is being studied in normal volunteers.
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Conclusions
Despite a trend to improvement in motor scores, there is no evidence that amphetamines improve outcome in ischaemic stroke. Furthermore, there are significant haemodynamic effects, the consequences of which remain unclear but may have implications on prognosis. As such, doubt persists regarding the safety of amphetamine treatment. Further clinical trials are needed to further assess safety, and if appropriate, to define an optimal treatment regime. 
